Cargando…
Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
Around 40% of high-risk prostate cancer patients who undergo radiotherapy (RT) will experience biochemical failure. Chemotherapy, such as docetaxel (DTX), can enhance the efficacy of RT. Multidrug resistance mechanisms often limit drug efficacy by decreasing intracellular concentrations of drugs in...
Autores principales: | Mirjolet, Céline, Boudon, Julien, Loiseau, Alexis, Chevrier, Sandy, Boidot, Romain, Oudot, Alexandra, Collin, Bertrand, Martin, Etienne, Joy, Pattayil Alias, Millot, Nadine, Créhange, Gilles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587207/ https://www.ncbi.nlm.nih.gov/pubmed/28919739 http://dx.doi.org/10.2147/IJN.S139167 |
Ejemplares similares
-
Titanate Nanotubes Engineered with Gold Nanoparticles and Docetaxel to Enhance Radiotherapy on Xenografted Prostate Tumors
por: Loiseau, Alexis, et al.
Publicado: (2019) -
About the Influence of PEG Spacers on the Cytotoxicity of Titanate Nanotubes-Docetaxel Nanohybrids against a Prostate Cancer Cell Line
por: Loiseau, Alexis, et al.
Publicado: (2021) -
Titanate nanoribbon-based nanobiohybrid for potential applications in regenerative medicine
por: Maurizi, Lionel, et al.
Publicado: (2022) -
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy
por: Schmitt, Esther, et al.
Publicado: (2015) -
Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein
por: Ghiringhelli, Francois, et al.
Publicado: (2016)